AZD 2927

Drug Profile

AZD 2927

Alternative Names: AZD2927

Latest Information Update: 09 Aug 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca
  • Class Antiarrhythmics
  • Mechanism of Action Ion channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Atrial fibrillation

Most Recent Events

  • 30 Jun 2012 Discontinued - Phase-II for Atrial fibrillation in Norway (IV)
  • 30 Jun 2012 Discontinued - Phase-II for Atrial fibrillation in Sweden (IV)
  • 13 Jan 2012 AstraZeneca completes a phase II trial in Atrial fibrillation in Sweden & Norway (NCT01396226)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top